Allogene Therapeutics (ALLO) Total Liabilities (2018 - 2026)
Allogene Therapeutics (ALLO) posted Total Liabilities of $117.1 million for Q1 2026, down 5.09% sequentially from $123.4 million in Q4 2025, and down 4.49% YoY from $122.6 million in Q1 2025.
Allogene Therapeutics (ALLO) Total Liabilities (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Total Liabilities for 9 years, with the latest figure at $117.1 million in Q1 2026.
- Quarterly Total Liabilities fell 4.49% year-over-year to $117.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.1 million (down 4.49% YoY) and the FY2025 annual result came in at $123.4 million, down 2.5% from the prior year.
- Total Liabilities slipped to $117.1 million in Q1 2026 per ALLO's latest filing, from $123.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $158.1 million in Q1 2023 and troughed at $112.8 million in Q1 2022.
- A 5-year average of $133.1 million and a median of $126.5 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 44.92% in 2022, then fell 20.96% in 2024.
- Over 5 years, Total Liabilities stood at $154.7 million in 2022, then slipped by 15.57% to $130.6 million in 2023, then retreated by 3.12% to $126.5 million in 2024, then decreased by 2.5% to $123.4 million in 2025, then dropped by 5.09% to $117.1 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $117.1 million, $123.4 million, and $124.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 113.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.92 Mn |
| Mar 31, 2026 | 117.08 Mn |
| Dec 31, 2025 | 123.36 Mn |
| Sep 30, 2025 | 124.44 Mn |
| Jun 30, 2025 | 126.03 Mn |
| Mar 31, 2025 | 122.59 Mn |
| Dec 31, 2024 | 126.53 Mn |
| Sep 30, 2024 | 125.37 Mn |
| Jun 30, 2024 | 131.85 Mn |
| Mar 31, 2024 | 124.98 Mn |
| Dec 31, 2023 | 130.60 Mn |
| Sep 30, 2023 | 132.78 Mn |
| Jun 30, 2023 | 151.60 Mn |
| Mar 31, 2023 | 158.12 Mn |
| Dec 31, 2022 | 154.70 Mn |
| Sep 30, 2022 | 151.08 Mn |
| Jun 30, 2022 | 149.14 Mn |
| Mar 31, 2022 | 112.82 Mn |
| Dec 31, 2021 | 125.63 Mn |
| Sep 30, 2021 | 109.30 Mn |